Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eleclazine PK in Hepatic Impairment
NCT02412098Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of eleclazine in long QT syndrome (LQTS), sponsored by Gilead Sciences. Primary endpoint: Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity of Eleclazine at Day 57. Started Mar 2015; status: completed.
02
Drugs
eleclazine
03
Conditions
long QT syndrome (LQTS)
Beyond the preview
Go deeper on NCT02412098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02412098.